Climb Bio Phase 1 Data Support CLYM116 Q12W Dosing in IgA Nephropathy
Wellesley Hills, Mass., September 3, 2026 Climb Bio announced positive initial Phase 1 clinical data for CLYM116, its investigational...
Phase 2 Trial
Advertisement
aTyr Pharma Prioritizes Efzofitimod as FDA Phase 3 Feedback Approaches
SAN DIEGO, August 7, 2026 aTyr Pharma reported its second quarter 2026 results and announced a corporate restructuring designed...
Kiora Pharmaceuticals Advances Key Clinical Programs
ENCINITAS, Calif., August 7, 2026 Kiora Pharmaceuticals reported second quarter 2026 financial results while highlighting continued progress across its...
Faeth Therapeutics to Present PIKTOR PK/PD Data
AUSTIN, Texas, August 7, 2026 Faeth Therapeutics announced that it will present new pharmacokinetic/pharmacodynamic (PK/PD) modeling and translational research...
Bavarian Nordic Secures EU Approval for IMVANEX in Children
COPENHAGEN, Denmark, August 7, 2026 Bavarian Nordic announced that the European Commission (EC) has approved a Type II variation...
Advertisements
Vistagen Reports Positive Phase 2 Fasedienol Repeat-Dose Data
SOUTH SAN FRANCISCO, Calif., August 6, 2026 Vistagen announced positive topline results from its exploratory Phase 2 repeat-dose clinical...
BioVie Advances Parkinson’s Program with Phase 2 Success
CARSON CITY, Nev., August 6, 2026 BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial, demonstrating...
LifeMine Raises $263M to Advance LIFE-001 Transplant Therapy
WATERTOWN, Mass., August 6, 2026 LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of...
Rhythm Pharmaceuticals Advances RM-718 with Promising Phase 2 Obesity Trial Results
BOSTON, August 4, 2026 Rhythm Pharmaceuticals announced encouraging preliminary Phase 2 clinical trial results for RM-718, its investigational once-weekly...
AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone
OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...
Advertisement
